Thursday, November 26, 2020

TOP 4 Low Float Biotech Stocks To Consider Buying: ADiTx Therapeutics, Inc. (ADTX), USA Equities Corp. (USAQ), ARCA biopharma, Inc. (ABIO) and Cancer Genetics, Inc. (CGIX)

Must Read

3 OTCs With UP To 500% Gain Potential Short Term: Enzolytics Inc. (ENZC), Electromedical Technologies, Inc. (EMED) and North America Frac Sand, Inc. (NAFS)

Enzolytics, Inc. (OTC: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the...

TransAtlantic Capital Inc. (TACI) is a Cannabis Stock to Consider For The Big 2021 Rebound

The global pandemic has made the situation even worse, and investors now are looking for companies that will simply...

CyberSecurity: Recent Data Breaches Could Spark Investor Interest in GlobeX Data, Palo Alto Networks and CrowdStrike Holdings, Fortinet

Cybersecurity is a fast-evolving industry. According to Cybersecurity Ventures, global spending on information security will grow to $170.4 billion...

ADiTx Therapeutics, Inc.(NASDAQ: ADTX), a life sciences company, focuses on developing nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients and address autoimmune diseases and allergies. The company commercializes Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, skin grafting, autoimmune diseases, allergies, and other applications. The company has a license agreement with Loma Linda University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.

USA Equities Corp. (OTC: USAQ). On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income (MPI) a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are currently focused on value-based healthcare solutions, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardiometabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s now younger, obese, diabetic and cardiovascular disease population.

ARCA biopharma, Inc. (NASDAQ: ABIO) operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Cancer Genetics, Inc. (NASDAQ: CGIX), through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company’s clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest

3 OTCs With UP To 500% Gain Potential Short Term: Enzolytics Inc. (ENZC), Electromedical Technologies, Inc. (EMED) and North America Frac Sand, Inc. (NAFS)

Enzolytics, Inc. (OTC: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the...

TransAtlantic Capital Inc. (TACI) is a Cannabis Stock to Consider For The Big 2021 Rebound

The global pandemic has made the situation even worse, and investors now are looking for companies that will simply survive. There are only two...

CyberSecurity: Recent Data Breaches Could Spark Investor Interest in GlobeX Data, Palo Alto Networks and CrowdStrike Holdings, Fortinet

Cybersecurity is a fast-evolving industry. According to Cybersecurity Ventures, global spending on information security will grow to $170.4 billion in 2022. The cybersecurity market...

2 Beverage Stocks To Watch This Month: Splash Beverage Group, Inc.(SBEV), Monster Beverage Corporation (MNST)

Splash Beverage Group, Inc.(OTC: SBEV) is innovating the beverage industry with delicious, natural and healthy drinks that delight the body and inspire the mind. Splash...

Solar Integrated Roofing Corporation (SIRC) Could Benefit From The Democratic Party’s Plan To Expand Use of Renewable Energy in the U.S Over the Next...

The global solar energy market was valued at $52.5 billion in 2018 and is projected to reach $223.3 billion by 2026, growing at a...
- Advertisement -

More Articles Like This

- Advertisement -